High expression of FOXC1 is associated with non-small cell lung cancer patients.

Taken together, these data indicate that FOXC1 is a novel hypoxia-induced transcription factor and plays a critical role in tumor microenvironment-promoted lung cancer progression.

This study demonstrates that FOXC1 induces cancer stem cells (CSCs)-like properties in non-small cell lung cancer (NSCLC) by promoting beta-catenin expression. The findings indicate that FOXC1 is a potential molecular target for anti-CSC-based therapies in NSCLC

Study discovered that overexpression of FOXC1 significantly enhanced, whereas its knockdown significantly reduced, the capabilities of triple-negative breast cancer (TNBC) cell invasion and motility in vitro and metastasis to the lung in vivo. Also, FOXC1 enhanced the expression of CXCR4, probably through its transcriptional up-regulation in TNBC cells.